Uni-Bio Science Group Limited (HKG:0690)

Market Cap	985.25M
Revenue (ttm)	589.59M
Net Income (ttm)	91.35M
Shares Out	5.97B
EPS (ttm)	0.02
PE Ratio	10.92
Forward PE	n/a
Dividend	0.00 (1.68%)
Ex-Dividend Date	May 28, 2025

Volume	68,640,000
Average Volume	37,208,410
Open	0.1620
Previous Close	0.1600
Day's Range	0.1590 - 0.1670
52-Week Range	0.0510 - 0.1680
Beta	-0.04
RSI	62.76
Earnings Date	Aug 29, 2025

About Uni-Bio Science Group

Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 487
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0690

Financial Performance

In 2024, Uni-Bio Science Group's revenue was 552.98 million, an increase of 14.08% compared to the previous year's 484.72 million. Earnings were 82.77 million, an increase of 16.79%.